|
|
 |
|
Viewing report
|
|
|
|
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
Decision Resources, Inc., Jan 2009, Pages: 21
Generalized anxiety disorder (GAD) is a prevalent psychiatric disorder in the major pharmaceutical markets, and drug therapy is considered the most effective treatment. The therapy market for GAD is crowded and includes many generic players, creating a difficult environment for launching new agents. Nonetheless, several emerging agents are set to challenge current market leaders.
Get the Answers You Need to Shape Your Strategy
- GAD can be very debilitating, causing those affected to significantly limit their activities. How many people in the major pharmaceutical markets we cover (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) have GAD? What brain structures and neurotransmitters have been implicated in its development? How is the disease diagnosed?
- A variety of drug classes are used to treat GAD. What are the most popular therapies for GAD? What are their benefits and drawbacks?
- Several new agents for GAD should launch in the next few years. What agents are in the pipeline for GAD, and are they likely to replace any existing agents? What changes can be expected in the GAD market over the next five years?
Scope:
- Overview of GAD: disease description, diagnosis, and pathophysiology.
- Epidemiology: total prevalent cases, diagnosed and drug-treated populations.
- Current therapies: selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and benzodiazepines.
- Emerging therapies: Sanofi -Aventis’s Saredutant, Pfizer’s Lyrica, Pfizer’s PD-332334, Takeda/Lundbeck’s Lu AA21004, Synosia Therapeutics’ Rufi namide, Sepracor’s SEP-225441 and AstraZeneca’s AZD-7325.
- GAD market: 2007 statistics, outlook for emerging agents.
Customers who bought this item also bought
Anxiety Disorders - Viable Indication for Antipsychotics Companies
Disease and Therapy Review: Generalized Anxiety Disorder
R&D Update: What's on the Horizon for the Panic Disorder Market?
Strategic Perspectives 2001: Generalized Anxiety Disorder - Driven by Effexor and Open to Expansion
Anxiety Disorders - A Decade of Declining Revenues
The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007
Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging Market
Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market
Thought Leader Insight & Analysis: Anxiety & Depression
Anxiety, Phobias & Panic Disorders - 2009 Edition
Strategic Perspectives 2001: Social Anxiety Disorder - The Target Anxiety Market For Leading Players
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
|
|
|
|
